Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new public-private consortium (known as COMPACT) funded by the Innovative Medicines Initiative (IMI) of the EU recently launched a major new 30 million Euro project focussing on improving the delivery of biopharmaceutical drugs. The University of Oxford plays a leading
role in the consortium which also comprises experts from 14 academic institutions, two biotechnology companies and seven pharmaceutical companies. Professor Matthew Wood will lead all IMI work to develop improved methods for drug delivery to the brain. A major challenge in treating many currently incurable neurological diseases is to achieve effective drug delivery to the brain across the blood brain barrier (a natural barrier that protects the brain). This new IMI project aims to tackle this challenge within the next 5 years.